SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

Core Insights - SeaStar Medical Holding Corporation is presenting new analyses of clinical data supporting the immunomodulating effect of its Selective Cytopheretic Device (SCD) at the ASN 2024 Kidney Week [1][2] - The SCD has shown significant reduction in biomarkers related to inflammation in patients with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT) [2][3] - The SCD is designed to target proinflammatory cells and promote a reparative state, potentially aiding in long-term organ recovery [6][8] Company Developments - The SCD-Pediatric device, QUELIMMUNE™, received FDA approval as a Humanitarian Use Device in February 2024 for critically ill children with AKI [7] - The company is actively enrolling patients in its adult NEUTRALIZE-AKI pivotal trial and exploring other indications such as cardiorenal syndrome [3][8] - SeaStar Medical aims to have a significant presence at the ASN Kidney Week, showcasing multiple abstracts related to the SCD [3] Industry Context - ASN Kidney Week is a major event in nephrology, expected to attract over 12,000 kidney professionals globally, providing a platform for knowledge exchange and discussions on scientific advances [4] - Acute Kidney Injury (AKI) can lead to hyperinflammation, which may result in multi-organ dysfunction and increased healthcare costs due to prolonged ICU stays and reliance on dialysis [5] - The SCD's unique immunomodulation approach may address the challenges posed by hyperinflammation in AKI and other related conditions [6][8]